Comparative Pharmacology
Head-to-head clinical analysis: ACTICORT versus ASMANEX HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICORT versus ASMANEX HFA.
ACTICORT vs ASMANEX HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
None Documented
None Documented
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Category C
Category C
Corticosteroid
Corticosteroid, Inhaled